Development of Nanomedicine for Cancer Therapy

Nanomedicine represents a revolutionary shift in oncological treatment by utilizing nanoscale materials to diagnose, monitor, and treat cancer with high precision. By operating at the molecular scale (typically between 1 and 100 nanometers), nanomedicine bypasses the biological barriers that limit standard therapies, offering a path toward highly effective and personalized cancer management. Nanomedicine for cancer therapy uses microscopic carriers—such as liposomes, polymeric nanoparticles, and dendrimers—to deliver drugs directly to tumors. This approach improves drug stability, increases concentration at the tumor site, and reduces damage to healthy tissues

Nanomedicine for Cancer Therapy will be developed the Academy with the expertise from the renowned the Accademia Nazionale di Medicina (AccMed), Italy. The research is targeted is targeted drug delivery, minimizing systemic toxicity, and overcoming multi-drug resistance. Nanoparticles research will achieve this by exploiting unique tumor physiological traits to improve the therapeutic index of anti-cancer agents.

The research outcome of nanomedicine for cancer therapy is expected show improved targeted drug delivery, reduced toxic side effects, and enhanced combination therapies. It will also transform treatment by offering precise drug targeting, reduced side effects, and enhanced drug stability.